During tumor development, loss of heterozygosity (LOH) often occurs. When LOH is preceded by an oncogene activating mutation, the mutant allele may be further potentiated if the wild-type allele is lost or inactivated. In myeloproliferative neoplasms (MPN) somatic acquisition of JAK2V617F may be followed by LOH resulting in loss of the wild type allele. The occurrence of LOH in MPN and other proliferative diseases may lead to a further potentiating the mutant allele and thereby increasing morbidity. A real time PCR based SNP profiling assay was developed and validated for LOH detection of the JAK2 region (JAK2LOH). Blood of a cohort of 12 JAK2V617F-positive patients (n = 6 25–50% and n = 6>50% JAK2V617F) and a cohort of 81 patients suspected of MPN was stored with EDTA and subsequently used for validation. To generate germ-line profiles, non-neoplastic formalin-fixed paraffin-embedded tissue from each patient was analyzed. Results of the SNP assay were compared to those of an established Short Tandem Repeat (STR) assay. Both assays revealed JAK2LOH in 1/6 patients with 25–50% JAK2V617F. In patients with >50% JAK2V617F, JAK2LOH was detected in 6/6 by the SNP assay and 5/6 patients by the STR assay. Of the 81 patients suspected of MPN, 18 patients carried JAK2V617F. Both the SNP and STR assay demonstrated the occurrence of JAK2LOH in 5 of them. In the 63 JAK2V617F-negative patients, no JAK2LOH was observed by SNP and STR analyses. The presented SNP assay reliably detects JAK2LOH and is a fast and easy to perform alternative for STR analyses. We therefore anticipate the SNP approach as a proof of principle for the development of LOH SNP-assays for other clinically relevant LOH loci.
References
[1]
Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, et al. (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365: 1054–1061.
[2]
James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, et al. (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434: 1144–1148.
[3]
Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, et al. (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352: 1779–1790.
[4]
Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, et al. (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7: 387–397.
[5]
Schindler C, Darnell JE Jr (1995) Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. Annu Rev Biochem 64: 621–651.
[6]
Steensma DP (2006) JAK2 V617F in myeloid disorders: molecular diagnostic techniques and their clinical utility: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology. J Mol Diagn 8: 397–411; quiz 526.
[7]
Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, et al. (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114: 937–951.
[8]
Yamamoto G, Nannya Y, Kato M, Sanada M, Levine RL, et al. (2007) Highly sensitive method for genomewide detection of allelic composition in nonpaired, primary tumor specimens by use of affymetrix single-nucleotide-polymorphism genotyping microarrays. Am J Hum Genet 81: 114–126.
[9]
Scott LM, Scott MA, Campbell PJ, Green AR (2006) Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia. Blood 108: 2435–2437.
[10]
Vannucchi AM, Antonioli E, Guglielmelli P, Rambaldi A, Barosi G, et al. (2007) Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood 110: 840–846.
[11]
Passamonti F, Rumi E (2009) Clinical relevance of JAK2 (V617F) mutant allele burden. Haematologica 94: 7–10.
[12]
Antonioli E, Guglielmelli P, Poli G, Bogani C, Pancrazzi A, et al. (2008) Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia. Haematologica 93: 41–48.
[13]
Vannucchi AM, Antonioli E, Guglielmelli P, Longo G, Pancrazzi A, et al. (2007) Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukemia 21: 1952–1959.
[14]
Barosi G, Bergamaschi G, Marchetti M, Vannucchi AM, Guglielmelli P, et al. (2007) JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood 110: 4030–4036.
[15]
Dupont S, Masse A, James C, Teyssandier I, Lecluse Y, et al. (2007) The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera. Blood 110: 1013–1021.
[16]
Larsen TS, Pallisgaard N, Moller MB, Hasselbalch HC (2007) The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis–impact on disease phenotype. Eur J Haematol 79: 508–515.
[17]
Tefferi A, Lasho TL, Schwager SM, Strand JS, Elliott M, et al. (2006) The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera. Cancer 106: 631–635.
[18]
Huijsmans CJ, Poodt J, Savelkoul PH, Hermans MH (2011) Sensitive detection and quantification of the JAK2V617F allele by real-time PCR blocking wild-type amplification by using a peptide nucleic acid oligonucleotide. J Mol Diagn 13: 558–564.
[19]
Kissel HD, Galipeau PC, Li X, Reid BJ (2009) Translation of an STR-based biomarker into a clinically compatible SNP-based platform for loss of heterozygosity. Cancer Biomark 5: 143–158.
[20]
Watling CJ, van Meyel DJ, Ramsay DA, Macdonald DR, Cairncross JG (1995) Loss of heterozygosity analysis of chromosomes 9, 10 and 17 in gliomas in families. Can J Neurol Sci 22: 17–21.
[21]
Jen J, Kim H, Piantadosi S, Liu ZF, Levitt RC, et al. (1994) Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med 331: 213–221.
[22]
Lanza G, Matteuzzi M, Gafa R, Orvieto E, Maestri I, et al. (1998) Chromosome 18q allelic loss and prognosis in stage II and III colon cancer. Int J Cancer 79: 390–395.
[23]
Ogunbiyi OA, Goodfellow PJ, Herfarth K, Gagliardi G, Swanson PE, et al. (1998) Confirmation that chromosome 18q allelic loss in colon cancer is a prognostic indicator. J Clin Oncol 16: 427–433.
[24]
Huijsmans R, Damen J, van der Linden H, Hermans M (2007) Single nucleotide polymorphism profiling assay to confirm the identity of human tissues. J Mol Diagn 9: 205–213.
